Drug
forodesine hydrochloride
forodesine hydrochloride is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
5
100%
Phase Distribution
5
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
5(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(5)
Detailed Status
Completed5
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 15 (100.0%)
Trials by Status
completed5100%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_1
Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients
NCT01776411
completedphase_1
Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies
NCT00823355
completedphase_1
Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma
NCT00098332
completedphase_1
BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma
NCT00061880
completedphase_1
BCX-1777 in Treating Patients With Refractory Cancer
NCT00073944
Clinical Trials (5)
Showing 5 of 5 trials
NCT01776411Phase 1
Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients
NCT00823355Phase 1
Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies
NCT00098332Phase 1
Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma
NCT00061880Phase 1
BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma
NCT00073944Phase 1
BCX-1777 in Treating Patients With Refractory Cancer
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5